Mutant Abl kinases (such as BCR-Abl) drive the development of leukemia; however little is known regarding whether Abl kinases contribute to the development or progression of solid tumors. We recently demonstrated that endogenous Abl kinases (c-Abl, Arg) are activated by deregulated ErbB receptors and Src kinases, and drive invasion of aggressive breast cancer cells. In this study, we examined whether activation of endogenous Abl kinases affects transformation, proliferation and survival, which are major contributors to breast cancer development and metastatic progression. Using a pharmacological inhibitor and RNAi, we demonstrate that activation of endogenous Abl kinases dramatically promotes breast cancer cell proliferation and anchorage-independent growth in serum, as well as survival following nutrient deprivation. Activation of Abl kinases mediates phosphorylation of STAT3, and promotes proliferation by accelerating G 1 -S progression. Moreover, we identify IGF-1R as a novel upstream activator of endogenous Abl kinases, and demonstrate that Abl kinase activation is required for IGF-1-stimulated cell cycle progression in breast cancer cells. Since activation of Abl kinases affects multiple steps of breast cancer development and progression, Abl kinase inhibitors are likely to be effective agents for the treatment of breast cancers containing highly active Abl kinases.
Introduction
Malignant transformation results from an accumulation of genetic alterations that allow cells to grow autonomously, independent of mitogens secreted by neighboring cells, accelerate the cell cycle, evade apoptosis and acquire unlimited replicative potential (Hanahan and Weinberg, 2000) . Tumors progress to a metastatic state by acquiring additional alterations that allow them to induce angiogenesis, invade neighboring tissues, intravasate blood vessels and survive in the circulatory system, extravasate, attach, survive and proliferate in a new environment, and reactivate angiogenesis (Hanahan and Weinberg, 2000) . Mitogenic independence, increased proliferation and escape from apoptosis thus are important steps not only in the development of malignancy, but also in progression of the disease, since both increased proliferation and survival serve as poor prognostic indicators (Wu et al., 1999; van Diest et al., 2004) .
Breast cancer is the second leading cause of cancerrelated mortality in US women (Jemal et al., 2007) . Identifying deregulated signaling molecules that contribute to breast cancer development and progression is essential for designing novel therapeutic agents. Deregulation of ErbB (epidermal growth factor receptor, (EGFR/ErbB1), Her-2/ErbB2) and insulin-like growth factor receptor (IGF-1R), Ras/extracellular signal-regulated kinase (ERK), phosphoinositide 3-kinase (PI3K)/ Akt and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways contribute to aberrant proliferation of breast cancer cells and increase cell survival (Chernicky et al., 2000; Hynes, 2000; Buettner et al., 2002; Santen et al., 2002; Morgensztern and McLeod, 2005) . Activation of ErbB family members, IGF-1R and Src kinases also promotes breast cancer progression by increasing metastasis, and their activation is associated with a poor clinical outcome (Hynes, 2000; Chernicky et al., 2002; Holbro and Hynes, 2004) .
The Abelson family of nonreceptor tyrosine kinases (Abl kinases) consists of c-Abl and Abl-related gene (Arg), encoded by Abl1 and Abl2 genes, respectively. Abl kinases are tightly regulated by intermolecular (inhibition by regulatory binding partners) and intramolecular (auto-inhibition) interactions (Pendergast, 2002) . Disruption of inhibitory bonds coupled with tyrosine phosphorylation in the activation loop (Y412) and in the interlinker region (Y245) results in Abl kinase activation (Pendergast, 2002) . Previously, we and others showed that Abl kinases are activated, in fibroblasts, by growth factors such as platelet-derived growth factor via Src kinases, which phosphorylate Abl kinases on Y412 and Y245 (Pendergast, 2002) . Chromosomal translocation of Abl1 and Abl2 next to breakpoint cluster region (BCR) and Tel genes generates mutant, constitutively active kinases (BCRAbl, Tel-Abl, Tel-Arg) that drive the development of several forms of leukemia and myeloproliferative disease, in part, by upregulating proliferation and inhibiting apoptosis (Pendergast et al., 2001) . Gleevec (STI571, imatinib mesylate), an Abl kinase inhibitor, induces remission in patients with early stage, BCR-Ablpositive chronic myelogenous leukemia (Druker et al., 2001) .
Although the mechanism by which BCR-Abl drives leukemogenesis is well understood, there is little information regarding whether Abl proteins affect the development or progression of solid tumors. Recently, we demonstrated that Abl kinases are highly active in many invasive breast cancer cell lines, and dramatically enhance invasion, an essential step in the metastatic process (Srinivasan and Plattner, 2006) . Here, we show for the first time, that activation of Abl kinases also is required for several other processes critical for breast cancer development and progression: cell cycle progression and proliferation, anchorage-independent growth and survival.
Results
Activation of Abl kinases is required for maintenance of the transformed phenotype c-Abl and Arg are dramatically activated in several poorly differentiated, highly invasive breast cancer cell lines (MDA-MB-435s, MDA-MB-231, BT-549, MDA-MB-468) but not in well-differentiated, noninvasive MCF-7 breast cancer cells, and activation of Abl kinases dramatically increases breast cancer cell invasiveness (Srinivasan and Plattner, 2006) . To determine whether activation of Abl kinases affects other processes critical for breast cancer development and/or progression, we tested whether Abl kinase activation is required for maintaining the transformed phenotype of breast cancer cells using soft-agar assays. Ten micromolar STI571 was utilized because this concentration is required to effectively decrease c-Abl phosphorylation and activity (65-75%) in MDA-MB-435s and BT-549 cells (Srinivasan and Plattner, 2006) . In the presence of STI571, the size (Figure 1a , bottom) and number ( Figure 1a , top) of soft-agar colonies was drastically reduced.
Silencing c-Abl and Arg by RNA interference (RNAi), in MDA-MB-435s cells, which have highly active Abl kinases, also dramatically reduced the number of colonies formed in soft agar (Figure 1b) . Knockdown efficiencies were determined by western blotting, kinase assay and semiquantitative reverse transcription (RT)-PCR ( Figure 1c ). Endogenous Arg expression is not easily detected by western blot, but kinase assays and RT-PCR give an approximate estimate of Arg knockdown efficiency (Srinivasan and Plattner, 2006) . Due to the high degree of sequence homology between c-Abl and Arg, the c-Abl siRNA modestly inhibited Arg expression and vice versa (Figure 1c ).
Abl kinase activation enhances breast cancer cell proliferation and promotes phosphorylation of STAT3 STI571 treatment of breast cancer cells containing highly active Abl kinases (MDA-MB-468, MDA-MB-231, BT-549 and MDA-MB-435s) profoundly reduced the growth rate of cells in serum, while growth of MCF-7 cells, which have low c-Abl and Arg kinase activities, was not significantly affected ( Figure 2a) . Strikingly, in MDA-MB-231 and MDA-MB-468 cells, STI571 treatment induced growth arrest (plateau in the curve; Figure 2a ). Treatment with STI571 also drastically reduced tritiated thymidine uptake at 24 h in several breast cancer cell lines, which indicates a decrease in S-phase cells (Figure 2b , left). In MDA-MB-231 cells, STI571 did not inhibit tritiated thymidine incorporation at 24 h (Figure 2b , left), even though growth kinetic curves indicated an effect on growth (Figure 2a ). Trypan blue assays showed that STI571 did not increase cell death (data not shown). To determine whether the discrepancy was due to the fact that the tritiated thymidine assay was carried out at a time point when there were no differences in the growth curve (Figure 2a) , we carried out the assay at a later time point. Tritiated thymidine incorporation was reduced following treatment with STI571 for 5 days (Figure 2b , right). STI571 had no effect on tritiated thymidine uptake in MCF-7 cells, which have low c-Abl and Arg activities (Figure 2b, left) . Furthermore, a dosedependent decrease in tritiated thymidine incorporation was observed in MDA-MB-435s cells, which contain high c-Abl and Arg kinase activities, while MCF-7 cells were relatively unaffected by STI571 treatment (Figure 2c ). Significantly, silencing Arg in MDA-MB435s and BT-549 cells also decreased tritiated thymidine incorporation, similar to the effect observed with STI571, while silencing c-Abl had no effect ( Figures  2d and e) .
Unregulated breast cancer cell proliferation is mediated by activation of signaling pathways including JAK/STAT, Ras/ERK and PI3K/Akt (Buettner et al., 2002; Santen et al., 2002; Morgensztern and McLeod, 2005) . To identify the mechanism by which Abl kinases enhance proliferation, we assessed the phosphorylation status of JAKs, STATs, ERK and Akt in STI571-treated MDA-MB-435s cells. Phosphorylation of STAT1 and STAT3 on Y701 and Y705, respectively, correlates with STAT activity and DNA-binding capability (Widschwendter et al., 2002) . STAT1 and STAT3 phosphorylation were significantly decreased following STI571 treatment, while phosphorylation of STAT5, JAK1, JAK2, Akt and ERK2 was not altered, and phosphorylation of ERK1 actually increased following prolonged treatment (Figures 3a and c; data not shown). Transfection of c-Abl and Arg siRNAs also significantly decreased phosphorylation of STAT3 and increased ERK1 phosphorylation, similar to the effects observed with STI571 (Figures 3b and d) , but had no effect on phosphorylation of JAK1, JAK2, Akt and no significant effect on STAT1 phosphorylation (data not shown).
Activation of Abl kinases is required for growth and survival following serum withdrawal Proliferation in the absence of nutrients is critical for tumor formation and metastasis, because cancer cells must survive and proliferate in a low-nutrient environment before angiogenesis, and metastatic cells must be able to grow and divide at ectopic sites, which lack certain cell-type specific growth factors (Kauffman et al., 2003) . To test whether activated Abl kinases support survival of breast cancer cells under lownutrient conditions, we evaluated the ability of cells, treated with STI571, to survive and grow in low serum (0.1% fetal bovine serum, FBS). All breast cancer cell lines were able to survive and divide in low serum, and treatment with STI571 markedly inhibited their ability to proliferate as assessed by growth kinetic (Figure 4a ) and tritiated thymidine (Figure 4b ) assays. Significantly, prolonged exposure to STI571 induced dramatic cell death (downhill slope; Figure 4a ). Silencing Arg, but not c-Abl, also reduced tritiated thymidine incorporation in both MDA-MB-435s and BT-549 cells (Figures 4c  and d) .
Interestingly, STI571 also inhibited proliferation of MCF-7 cells in low serum, even though these cells have low c-Abl and Arg kinase activities (Figures 4a and b) , and both MDA-MB-435s cells and MCF-7 cells exhibited a concentration-dependent decrease in tritiated thymidine uptake (Figure 4e ). MCF-7 cells secrete stem cell factor (SCF) and express a phosphorylated form of the SCF receptor, c-Kit (a STI571 target) (data not shown; Hines et al., 1995; Druker et al., 1996) . Therefore, the effects of STI571 on MCF-7 cell survival in nutrient-deprived conditions may be mediated by inhibition of c-Kit (see next section). Notably, c-Kit is not expressed in any of the other breast cancer cell lines in our study except MDA-MB-468 (Srinivasan and Plattner, 2006) . 
Activated Abl kinases protect breast cancer cells from serum deprivation-induced apoptosis
To determine whether STI571 induces apoptosis in nutrient-deprived conditions, we assessed the effect of STI571 treatment on the cleavage of poly-(ADPribose) polymerase (PARP), a nuclear polymerase that is cleaved from 115 to 89 kDa by caspase-3/-7 during apoptosis (Burkle, 2005) . Significantly, STI571 treatment of MCF-7, MDA-MB-468, MDA-MB-231 and BT-549 cells, grown in low-nutrient conditions, induced PARP cleavage (Figure 5a ). In addition, the PARP cleavage product was detected in serum-deprived BT- 
IGF1-R is a novel activator of Abl kinases
Abl kinases are activated downstream of activated EGFR/Her-2 receptors in breast cancer cells (Srinivasan and Plattner, 2006) . A related receptor tyrosine kinase, IGF-1R, enhances breast cancer cell transformation, proliferation and survival, and promotes tumorigenesis, in vivo (Chernicky et al., 2000) . Furthermore, IGF-1R and c-Abl are coexpressed in breast tumors and in breast cancer cell lines (Singer et al., 2004; Srinivasan and Plattner, 2006) . To determine whether Abl kinases are activated downstream of IGF-1R, we stimulated MCF-7 cells (express IGF-1R and have low c-Abl and Arg kinase activities) (Srinivasan and Plattner, 2006) with IGF-1, and evaluated the effect on c-Abl and Arg. c-Abl and Arg were activated B2-to 3-fold following IGF-1 stimulation (Figure 6a ). Due to extremely high c-Abl and Arg activities in MDA-MB-435s cells, we were unable to detect increases in the activities of c-Abl and Arg in response to IGF-1 in this cell line (data not shown). To determine whether IGF-1R activity contributes to the high endogenous activities of Abl kinases in MDA-MB-435s cells (express IGF-1R but not ErbB receptors) (Srinivasan and Plattner, 2006) , we blocked IGF-1R activity using a pharmacological inhibitor, AG1024, or silenced IGF-1R expression with RNAi. c-Abl and Arg activation was reduced in AG1024-treated or IGF-1R siRNA-transfected MDA-MB-435s cells grown in the absence of serum or exogenous IGF-1 (Figures 6b and c) . AG1024 had no effect on c-Abl or Arg kinase activities in serum-starved fibroblasts or MCF-7 cells, which indicates that AG1024 does not directly inhibit c-Abl or Arg (Figure 6b ; data not shown). Since activated Src kinases contribute to activation of Abl kinases in MDA-MB-435s cells (Srinivasan and Plattner, 2006) , we tested whether IGF-1R activates Abl kinases by upregulating Src kinase activity. Inhibition or silencing of IGF-1R did not decrease constitutive Src phosphorylation, which indicates that IGF-1R activates Abl kinases independent of Src (Figures 6b and c, bottom) .
Activation of Abl kinases by IGF-1R is required for IGF-1-mediated cell cycle progression To determine whether Abl kinases play a functional role in IGF-1R-mediated proliferation, we tested whether inhibiting c-Abl and Arg kinase activities blocks IGF-1-induced cell cycle progression. IGF-1 stimulation of serum-starved, G 1 -phase MDA-MB-435s cells induced G 1 to S-phase progression, which was dramatically blocked by pretreatment of cells with STI571 ( Figures  7b-d, middle) . Significantly, the peak S-phase fraction also was dramatically reduced in STI571-treated cells (Figure 7e ). Some G 1 -synchronized MDA-MB-435s cells were able to enter S phase in the absence of growth factor or serum stimulation, which indicates either that MDA-MB-435s cells secrete autocrine factors that induce cell cycle progression, or that proliferation pathways are constitutively active in these cells ( Figures  7b-d, left) . Pretreatment of cells with STI57I completely blocked the ability of MDA-MB-435s cells to transit from G 1 to S in the absence of exogenous growth factors Abl kinases in breast cancer D Srinivasan et al (Figures 7b-d, left) , and significantly slowed seruminduced S-phase entry (Figures 7b-d, right) . Therefore, in MDA-MB-435s cells, Abl kinases are absolutely required for transit from G 1 -S in response to IGF-1 stimulation and in serum-deprived conditions, and accelerate cell cycle progression in response to serum, which contains a variety of growth-promoting agents.
Discussion
Previously, we demonstrated that activation of Abl kinases promotes invasion of aggressive breast cancer cells, and here we show that activated Abl kinases are also required for other processes critical for breast cancer development and progression: anchorage-independent growth, proliferation and inhibition of nutrient deprivation-induced apoptosis. Significantly, activation of Abl kinases promotes phosphorylation of STAT3 but not ERK or Akt, and Abl kinase activation increases breast cancer cell proliferation by accelerating G 1 to S transition. Additionally, we uncover a novel activator of Abl kinases in breast cancer cells (IGF-1R), and show that G 1 -S progression induced by IGF-1 requires activation of Abl kinases. Blocking Abl kinase activation with STI571 potently reduces the growth of breast cancer cells in soft agar. In MDA-MB-435s cells, activation of both c-Abl and Arg is required for soft-agar growth, which suggests that the two kinases lie in parallel, necessary pathways to maintain the transformed phenotype. Blocking c-Abl and Arg kinase activities with STI571 also inhibits proliferation of breast cancer cells containing activated Abl kinases. However, unlike soft-agar assays, silencing Arg but not c-Abl decreases the proliferation rate of MDA-MB-435s and BT-549 cells in anchorage-dependent conditions. These novel results suggest that the two 
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Abl kinases have nonredundant functions, and indicate that the reason that both Abl kinase siRNAs dramatically inhibit soft-agar growth is not due to the modest inhibition of Arg by the Abl siRNA and vice versa as the same siRNAs were used for tritiated thymidine and soft-agar assays with similar knockdown efficiencies. Therefore, it is more likely that activation of c-Abl is important for enabling cells to grow in the absence of anchorage, whereas Arg activation enhances proliferation both in anchorage-dependent and anchorageindependent conditions. JAK/STAT, Ras/ERK and PI3K/Akt pathways are upregulated in breast cancer and promote breast cancer cell proliferation and survival (Buettner et al., 2002; Santen et al., 2002; Morgensztern and McLeod, 2005) . Significantly, inhibition or silencing activated Abl kinases in MDA-MB-435s cells dramatically decreases STAT3 phosphorylation. STAT1 and STAT3 are constitutively phosphorylated in many breast cancer cell lines and primary breast tumors, and activation of STAT3 promotes breast cancer cell proliferation (Buettner et al., 2002) . Therefore, Abl kinases may increase breast cancer cell proliferation by upregulating STAT3 activity. Interestingly, both c-Abl and Arg siRNAs inhibited STAT3 phosphorylation, while only the Arg siRNA inhibited proliferation. Since the Arg siRNA inhibited STAT3 phosphorylation more efficiently than c-Abl (5874 vs 4575%), there may be a threshold of STAT3 inhibition necessary to affect proliferation. Alternatively, there may be unique, Argdependent signaling pathways not yet tested, which are required for promoting proliferation. The effect of STI571 on STAT1 phosphorylation could not be confirmed by RNAi, which suggests that another STI571 target may be responsible for phosphorylating STAT1. Unlike STAT3, the function of STAT1 activation in breast cancer is unclear, as it inhibits cell growth in some contexts and promotes growth in others (Marra et al., 1996; Levy and Gilliland, 2000) .
In response to interferon-g, cytokine receptors activate JAK kinases, which in turn phosphorylate the STATs, while in other cell types and in response to other stimuli, activation of STATs does not require JAK activation (Buettner et al., 2002) . Here, we show that Abl kinases in breast cancer D Srinivasan et al activation of Abl kinases increases STAT3 but not JAK phosphorylation in MDA-MB-435s cells. Mutant, constitutively active forms of Abl (BCR-Abl, v-Abl) also activate STATs: v-Abl activates STAT1, -3 and -5 in a JAK-dependent manner, while BCR-Abl induces phosphorylation of STAT1, -3 and -5 in a JAK-independent manner (Danial et al., 1998; Pendergast et al., 2001) . Future experiments will determine whether activated, endogenous Abl kinases induce STAT3 phosphorylation directly or indirectly.
v-Abl and BCR-Abl also activate Ras/ERK and PI3K/Akt pathways, and activation of both of these pathways is essential for proliferation, survival and leukemogenesis (Kharas and Fruman, 2005) . Interestingly, activation of Abl kinases in breast cancer cells does not induce activation of either pathway. These data indicate that the mechanism by which Abl kinases promote proliferation of breast cancer cells differs from BCR-Abl-and v-Abl-mediated proliferation and oncogenesis. Paradoxically, inhibiting or silencing Abl kinases increases ERK1 phosphorylation. Erk1 activation may be a compensatory mechanism to overcome the growth inhibitory effects of silencing or inhibiting Abl kinases. Alternatively, ERK1 may inhibit proliferation, since ERK1, but not ERK2 blocks Ras-induced proliferation and transformation (Vantaggiato et al., 2006) .
We are the first to demonstrate that inhibiting Abl kinase activation abrogates serum-independent growth of breast cancer cells both by blocking G 1 -S progression and inducing apoptosis. In BT-549 cells, grown in low-nutrient conditions, c-Abl and Arg are both required for survival, and Arg promotes proliferation. These data indicate that activation of Abl kinases may be an important mechanism by which breast cancer cells suppress apoptosis to survive and grow at ectopic sites during metastasis.
There is conflicting evidence regarding the role of Abl kinases in proliferation and cell survival: c-Abl promotes proliferation, cell cycle progression and/or cell survival in some contexts, and inhibits growth and/or cell viability in others (Pendergast, 2002; Plattner and Pendergast, 2003; Nagano et al., 2006; Noren et al., 2006) . Our data are consistent with that of mutant, constitutively active forms of Abl such as BCR-Abl, which potently upregulate cellular proliferation and promote survival (Pendergast et al., 2001) . Abl kinases may have opposing effects on proliferation or survival depending on the cell context and/or stimulus. For example, exposure of breast cancer cells to ephrin B2 inhibits proliferation, survival and anchorage-independent growth in an Abl-dependent manner (Noren et al., 2006) , while we show that activation of Abl kinases by constitutively active growth factor receptors and Src kinases promotes anchorage-independent growth and proliferation of breast cancer cells in response to growth factor signals, and survival in response to growth factor withdrawal. The effect of Abl kinases on cell survival also may depend on their subcellular localization, since BCR-Abl which is localized in the cytoplasm and provides pro-survival signals, induces apoptosis when targeted to the nucleus (Vigneri and Wang, 2001 ). IGF-1 and its receptor (IGF1-R) promote breast cancer progression, and IGF-1R expression is associated with acquired resistance to ErbB inhibitors, which can be overcome by inhibiting IGF-1R (Nahta et al., 2005) . We identify IGF-1R as a novel upstream activator of Abl kinases, and demonstrate that activation of Abl kinases in breast cancer cells is required for IGF-1-mediated G 1 -S progression. Since Abl kinases are required for IGF-1-mediated signaling in breast cancer cells, inhibition of Abl kinases may be an effective way to treat breast cancers that develop resistance to ErbB inhibitors by upregulating IGF-1R. Additionally, since Abl kinases are activated by EGFR, IGF-1R and Src kinases, they represent a point of convergence between multiple pathways, and therefore drugs targeting Abl kinases are likely to be more effective than agents that inhibit a single pathway.
Materials and methods

Growth kinetic assays
Cells plated in 6-well dishes were treated with STI571, 24 h after plating (serum) or starvation, and counted on a hemacytometer. Cells were fed every 3 days with serumcontaining or serum-starvation media.
Tritiated thymidine assays
Cells plated in 12-well dishes were treated with STI571, labeled with tritiated thymidine (5 mCi) and harvested (Plattner and Pendergast, 2003) . siRNA-transfected cells were replated in 12-well dishes (1 Â 10 5 /well), allowed to attach, serum-starved, labeled and harvested.
Cell cycle analysis Cells with G 1 DNA content were isolated by flow sorting from asynchronous cells stained with Hoechst 33342 (1 mg/ml) and labeled with bromodeoxyuridine (BrdU; 10 mM) for 30 min at 371C. Sorted cells were rinsed with basal media, and plated on poly-D-lysine-coated dishes (60 mg/ml) in 0.1% FBS (Liliensiek et al., 2006) . Attached cells were pretreated for 2 h with STI571, left unstimulated or stimulated with 5 nM IGF-1 or 10% FBS for the indicated times, labeled with BrdU, stained with fluorescein isothiocyanate-conjugated anti-BrdU antibody and propidium iodide (PI, 5 mg/ml) (BD Biosciences protocol, Chicago, IL, USA) and analysed by fluorescenceactivated cell sorting (FACS) using Cell Quest software (BD Biosciences) and Modfit analysis (Verity Software House, Topsham, ME, USA) (University of Kentucky Flow Cytometry Facility; MoFlo FACS; DAKO, Denmark). To assess sort purity, an aliquot of sorted cells were stained and analysed.
